Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
IPO Year: 2013
Exchange: NASDAQ
Website: veracyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | $55.00 | Outperform | Wolfe Research |
| 4/13/2026 | $45.00 | Buy | Jefferies |
| 12/2/2025 | $48.00 | Underweight | Morgan Stanley |
| 10/20/2025 | $40.00 | Hold | Canaccord Genuity |
| 3/20/2025 | $45.00 | Buy | Craig Hallum |
| 12/5/2024 | $38.00 → $37.00 | Buy → Neutral | Goldman |
| 11/15/2024 | $50.00 | Outperform | Wolfe Research |
| 10/16/2024 | $43.00 | Buy | UBS |
| 10/10/2024 | $40.00 | Buy | Guggenheim |
| 2/23/2024 | $30.00 → $33.00 | Buy | Needham |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
3 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
144 - VERACYTE, INC. (0001384101) (Subject)
SCHEDULE 13G - VERACYTE, INC. (0001384101) (Subject)
SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)
10-Q - VERACYTE, INC. (0001384101) (Filer)
8-K - VERACYTE, INC. (0001384101) (Filer)
DEF 14A - VERACYTE, INC. (0001384101) (Filer)
DEFA14A - VERACYTE, INC. (0001384101) (Filer)
SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)
8-K - VERACYTE, INC. (0001384101) (Filer)
144 - VERACYTE, INC. (0001384101) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wolfe Research resumed coverage of Veracyte with a rating of Outperform and set a new price target of $55.00
Jefferies initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00
Morgan Stanley resumed coverage of Veracyte with a rating of Underweight and set a new price target of $48.00
Canaccord Genuity initiated coverage of Veracyte with a rating of Hold and set a new price target of $40.00
Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00
Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously
Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00
UBS initiated coverage of Veracyte with a rating of Buy and set a new price target of $43.00
Guggenheim initiated coverage of Veracyte with a rating of Buy and set a new price target of $40.00
Needham reiterated coverage of Veracyte with a rating of Buy and set a new price target of $33.00 from $30.00 previously
Fastest customizable press release news feed in the world
Genomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies 10-year risk of recurrence to help personalize treatment decisions in patients with early-stage breast cancer On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient's ROR score a
Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate's utility in high-risk localized disease Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy (ADT plus enzalutamide), known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1 evidence for a genomic test guiding this d
Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spared chemotherapy without compromising outcomes Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the ASCO Annual Meeting, conc
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal investigators of OPTIMA, Professor of Breast Oncology at the University of Glasgow and Honorary Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, will join for the discussion. The conference call will be webcast live
Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO Annual Meeting in Chicago, taking place May 29 – June 2. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte's genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer. The OPTIMA stud
Veracyte, Inc. (NASDAQ:VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics company
Marks the first Medicare coverage decision for Veracyte's whole-genome sequencing-based TrueMRD platform and launch of the first test Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) for patients with muscle-invasive bladder cancer (MIBC). The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte's first molecular residual dis
VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at
Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. "We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets," said Marc Stapley, Veracyte's CEO. "Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launc
Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in bladder cancer and feature national-scal
Live Leadership Updates
VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief De
NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a
Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
Veracyte, Inc. (NASDAQ:VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company's legal functions and will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220228005304/en/Veracyte Appoints Annie McGuire as General Counsel (Photo: Business Wire) "We are delighted to welcome Annie to Veracyte," said Mr. Stapley. "She brings with her significant experience in Fortune 100 and other healthcare companies. Her proven leadership
Veracyte, Inc. (NASDAQ:VCYT), a global diagnostics company, today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company's global accounting operations, financial reporting and tax functions. He will report to Rebecca Chambers, Veracyte's chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005393/en/Veracyte Appoints Jonathan Wygant as Chief Accounting Officer (Photo: Business Wire) "We are thrilled to welcome Jonathan to Veracyte," said Ms. Chambers. "He brings a depth of expertise and experience leading acco
Veracyte, Inc. (NASDAQ:VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to Richard T. Kloos, M.D., Veracyte's executive medical director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005316/en/Joshua Klopper, M.D. (Photo: Business Wire) "Dr. Klopper is an exceptional addition to Veracyte's world-class medical team," said Dr. Kloos. "He was an investigator
Live finance-specific insights
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal investigators of OPTIMA, Professor of Breast Oncology at the University of Glasgow and Honorary Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, will join for the discussion. The conference call will be webcast live
Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. "We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets," said Marc Stapley, Veracyte's CEO. "Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launc
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/even
Grew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. "We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter," said Marc Stapley, Veracyte's chief executive officer. "We are achieving this growth while maintaining best-in-class profitability, with mo
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/motsphxv. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://inv
Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. "We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance," said Marc Stapley, Veracyte's chief executive officer. "We continue to advance our mission of transforming cancer care by generating high-quality evidence and clinical insights tha
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/kcexjtb4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.
Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. "Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth," said Marc Stapley, Veracyte's chief executive officer. "This strong result, combined with Afirma volume meeting our expectations and the resolution of the French subsidiary proceedings, has positioned us for in
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5gqvvmtt. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
This live feed shows all institutional transactions in real time.
SC 13G - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)